https://orcid.org/0000-0001-5074-2000
Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Martin Perez-Santos, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz & Gabriela Sánchez Esgua. (2022) Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert Opinion on Drug Discovery 17:12, pages 1341-1355.
Read now
Read now
Jorge Cebada, Martin Perez-Santos, Cindy Bandala, Eleazar Lara-Padilla, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millán-Pérez Peña, Eduardo Monjaraz, Amira Flores & Maricruz Anaya-Ruiz. (2021) OX40 agonists for cancer treatment: a patent review. Expert Opinion on Therapeutic Patents 31:1, pages 81-90.
Read now
Read now
Jorge Cebada, Amira Flores, Cindy Bandala, Ian Lizaliturri-Flores, Nemesio Villa-Ruano & Martin Perez-Santos. (2020) Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054. Expert Opinion on Therapeutic Patents 30:7, pages 487-494.
Read now
Read now
Lourdes Millán-Pérez Peña, Perez-Santos Martin, Irma Herrera-Camacho, Cindy Bandala & Maricruz Anaya-Ruiz. (2020) Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739. Expert Opinion on Therapeutic Patents 30:5, pages 307-311.
Read now
Read now
Cristina M Quintella, Heitor M Quintella, Mayla Rohweder & Guilherme M Quintella. (2020) Advances in patent applications related to cancer vaccine using CpG-ODN and OX40 association. Expert Opinion on Therapeutic Patents 30:4, pages 287-301.
Read now
Read now
Martin Perez-Santos, Tayde Guerrero-González, Eduardo Gómez-Conde, Jorge Cebada, Amira Flores & Nemesio Villa-Ruano. (2020) Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652. Expert Opinion on Therapeutic Patents 30:3, pages 159-162.
Read now
Read now
Martin Perez-Santos, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta & Lourdes Millán-Pérez Peña. (2020) Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536. Expert Opinion on Therapeutic Patents 30:2, pages 83-86.
Read now
Read now
Articles from other publishers (11)
Farangis Rastin, Hossein Javid, Mahsa Akbari Oryani, Nastaran Rezagholinejad, Amir-R. Afshari & Mehdi Karimi-Shahri. (2024) Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress. International Immunopharmacology 126, pages 111055.
Crossref
Crossref
Anna Kuzevanova, Natalya Apanovich, Danzan Mansorunov, Alexandra Korotaeva & Alexander Karpukhin. (2022) The Features of Checkpoint Receptor—Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition. Biomedicines 10:9, pages 2081.
Crossref
Crossref
Asal Barshidi, Vahid Karpisheh, Fatemeh Karimian Noukabadi, Fariba Karoon Kiani, Mohammad Mohammadi, Negin Afsharimanesh, Farbod Ebrahimi, Seyed Hossein Kiaie, Jamshid Gholizadeh Navashenaq, Mohammad Hojjat-Farsangi, Naime Majidi Zolbanin, Ata Mahmoodpoor, Hadi Hassannia, Sanam Nami, Pooya Jalali, Reza Jafari & Farhad Jadidi-Niaragh. (2022) Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model. Pharmaceutical Research 39:8, pages 1851-1866.
Crossref
Crossref
Fiona Hegi-Johnson, Stacey Rudd, Rodney J. Hicks, Dirk De Ruysscher, Joseph A. Trapani, Thomas John, Paul Donnelly, Benjamin Blyth, Gerard Hanna, Sarah Everitt, Peter Roselt & Michael P. MacManus. (2022) Imaging immunity in patients with cancer using positron emission tomography. npj Precision Oncology 6:1.
Crossref
Crossref
Negin Shokrgozar, Mehran Karimi, Hossein Golmoghaddam, Narges Rezaei, Vida Moayed, Sedigheh Sharifzadeh & Nargess Arandi. (2021) Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype. Annals of Hematology 100:10, pages 2463-2469.
Crossref
Crossref
Shima Makaremi, Zahra Asadzadeh, Nima Hemmat, Amir Baghbanzadeh, Alessandro Sgambato, Farid Ghorbaninezhad, Hossein Safarpour, Antonella Argentiero, Oronzo Brunetti, Renato Bernardini, Nicola Silvestris & Behzad Baradaran. (2021) Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. Biomedicines 9:9, pages 1075.
Crossref
Crossref
Martin Perez-Santos. (2021) Bispecific anti-OX40/5T4 antibodies for cancer treatment. Pharmaceutical Patent Analyst.
Crossref
Crossref
Lan Wang, Chuanfei Yu, Kaiqin Wang & Junzhi Wang. (2020) A reporter gene assay for measuring the bioactivity of anti‐LAG‐3 therapeutic antibodies. Luminescence 35:8, pages 1408-1415.
Crossref
Crossref
Huimin Du, Ziying Yi, Long Wang, Zhi Li, Bailin Niu & Guosheng Ren. (2020) The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy. International Immunopharmacology 78, pages 106113.
Crossref
Crossref
Quentin Lecocq, Katty Zeven, Yannick De Vlaeminck, Sandrina Martens, Sam Massa, Cleo Goyvaerts, Geert Raes, Marleen Keyaerts, Karine Breckpot & Nick Devoogdt. (2019) Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. Biomolecules 9:10, pages 548.
Crossref
Crossref
Asal Barshidi, vahid karpisheh, Fatemeh Karimian Noukabadi, Fariba Karoon Kiani, Negin Afsharimanesh, Farbod Ebrahimi, Seyed Hossein Kiaie, Pooya Jalali, Mohammad Hojjat-Farsangi, Naime Majidi Zolbanin, Ata Mahmoodpoor, hadi Hassannia, Sanam Nami, Reza Jafari & Farhad Jadidi-Niaragh. (2021) Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model. SSRN Electronic Journal.
Crossref
Crossref